NCT03604198Active, not recruitingPhase 2
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 125 (actual)
- First submitted
- 1 May 2018
- Start date
- 7 May 2018
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Corcept Therapeutics
- NCT number
- NCT03604198
- EU CT number
- 2024-514079-17-00
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 125
- From 7 May 2018 to the primary completion date, 31 Dec 2026
- 48 sites in 10 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Major Exclusion Criteria:
- Premature discontinuation from a relacorilant parent study
- Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism.
Who the study is looking for
- Major Inclusion Criteria:
- Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome
- According to the Investigator's opinion will benefit from continuing treatment with relacorilant.
Sex: All · Does not accept healthy volunteers
Sites (48)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.